INAF - PT. Indofarma Tbk

Rp 2.900

-90 (-3,10%)

JAKARTA. The surge in medical equipment sales became the primary contributor to the skyrocketing revenue of PT Indofarma Tbk (INAD). The revenue jumped 151.88% to IDR 373.20 billion from IDR 148.17 billion in Q1 2020.

The financial report of this state-owned pharmaceutical company revealed that the medical devices sales contributed IDR 175.49 billion, exponentially soaring by 698.13%. The medicine sales also grew 57.62% to IDR 197.72 billion. This performance led to the net profit attributable to the parent company of IDR 1.82 billion, turning the table from the loss of IDR 21.43 billion in 2020.

The Financial Director of PT Indofarma Tbk, Herry Triyatno, restated that medical equipment sales have become the main pillar of the company’s performance in Q1 2021, which is also expected to be the main growth driver for the rest of the year.

The constantly promising prospects within the medical equipment sector encouraged INAD to set the target revenue of IDR 2.55 trillion this year. The realisation of sales for last year was at IDR 1.72 trillion. INAD would also allocate up to IDR 31.4 billion to capital expenditure. This fund would be utilised in the maintenance of pharmaceutical and herbal devices, as well as medical devices. (AM/ZH)